Venneos GmbH, a Stuttgart, Germany-based biotech startup, raised a series A financing of undisclosed amount.
Backers included Born2Grow, a consortium of business angels and family offices, the High-Tech Gründerfonds and the Max Planck Society.
The company will use the funds to consolidate its market entry and to prepare new product generations and develop the technology further toward additional potential applications in the fields of pharmaceuticals, cosmetics and chemistry.
Led by David Wehner, Venneos is developing and marketing the CAN-Q, a silicon chip-based imaging system for analysing biological cells.
The technology is based on a silicon chip. Cells grow on this chip and it detects the electrical signals caused by cellular changes. The signals are then processed and can be represented in microscopy-like images. This enables to identify changes, e.g. in cell adhesion, that other technologies cannot detect.
These systems are used in research, especially in tumour biology, immunology, pharmacology and drug development.
Venneos was founded in 2014 as a spin-off of the Max Planck Society.